Lupin receives approval from USFDA for Penicillamine Tablets USP

▴ Lupin receives approval from USFDA for Penicillamine Tablets USP
Penicillamine Tablets USP, 250 mg, are indicated in the treatment of Wilson’s disease, Cystinuria, and in patients with severe, active rheumatoid arthritis

Pharma major Lupin Limited announced that it has received approval for its Penicillamine Tablets USP, 250 mg, from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent of Depen Tablets, 250 mg, of Mylan Specialty, L.P. The product would be manufactured at Lupin’s Nagpur facility and is expected to be launched shortly.

Penicillamine Tablets USP, 250 mg, are indicated in the treatment of Wilson’s disease, Cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy.

Penicillamine Tablets USP (RLD: Depen) had an annual sales of approximately USD 4 million in the U.S. (IQVIA MAT September 2020).

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas. Lupin is the 3rd largest pharmaceutical company in the U.S. by prescriptions and 5th in India by global revenues. The Company invests 9.6 % of its revenues on research and development.

Lupin has fifteen manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.

Tags : #LupinLimited #LatestNewsonLupinLimited1stNov #LatestUSFDAApproval1stDec #LatestPharmaNews1stDec #RheumatoidArthritis

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

India’s Clinical Trials Market: Can We Leap from Underdog to Global Leader?March 05, 2025
India’s GBS Outbreak: Is Contaminated Water Fueling a Paralysis Crisis? March 05, 2025
From Algorithms to Actual Care: Is India’s AI Healthcare Dream Real?March 04, 2025
Lung Regeneration: Can Science Give Preterm Babies a Second Breath?March 04, 2025
Lung Regeneration: Can Science Give Preterm Babies a Second Breath?March 04, 2025
Lung Regeneration: Can Science Give Preterm Babies a Second Breath?March 04, 2025
The Great Indian Fat Crisis: Are 440 Million Overweight Indians the Price of Modernity?March 04, 2025
Neovantage Innovation Park Showcases Life Sciences Infrastructure at BioAsia 2025, Hosts Ministerial Visit and Miltenyi Biotec InaugurationMarch 03, 2025
University of Manchester invites applications for MA Digital Media, Culture and SocietyMarch 03, 2025
#EndLeprosy pathway is through stopping stigma against affected personsMarch 03, 2025
1.5 Million Bottles Recalled: Is Your ADHD Medication Safe?March 03, 2025
Dressed for Trust: Why Doctors Must Wear White Aprons AgainMarch 03, 2025
India’s Pharma Revolution: Can New Regulatory Reforms Unleash a $42 Billion Industry?March 01, 2025
Pregnant and Pained: Is Paracetamol Poisoning Our Unborn Children?March 01, 2025
Are Your Idlis Poisoning You? The Hidden Dangers of Plastic in Indian KitchensMarch 01, 2025
Rela Hospital Launches India’s First Intestinal Rehabilitation Centre to Expand Treatment Horizons Beyond TransplantationFebruary 28, 2025
Rela Hospital Launches India’s First Intestinal Rehabilitation Centre to Expand Treatment Horizons Beyond TransplantationFebruary 28, 2025
Olympus Announces Milestone for iTind(TM) Device with Expanded Availability Across Major APAC MarketsFebruary 28, 2025
7 Simple Breathing Exercises to Strengthen Your LungsFebruary 28, 2025
MedGenome launches Campaign ‘Care for the Rare’ to promote early detection of Rare DiseasesFebruary 27, 2025